The applications of generative artificial intelligence (GenAI) have reached continuous glucose monitoring after DexCom launched rolled out the technology into its glucose biosensor products.
Built using Google Cloud’s Vertex AI platform and Gemini models, the Dexcom GenAI platform will analyse individual health data patterns to discern relationships between lifestyle choices and blood glucose levels. It will also recommend actions patients can follow to improve metabolic health.
Dexcom claims the launch of the GenAI platform is a “first” in glucose biosensing. The diabetes device giant said the first product to receive the Gen-AI-enabled technology would be Stelo, which became the first over-the-counter glucose biosensor in the US after it was cleared by the US Food and Drug Administration (FDA) in March.
Stelo users should receive an update, with improvements to the Weekly Insights feature’s personalised tips, recommendations, and education tools.
Dexcom’s executive vice president and chief operating officer Jake Leach said the launch “opens the door for future advancements across [Dexcom’s] product portfolio”.
He said: “We look forward to introducing additional GenAI-powered features over the next year to help users contextualise their health information and make proactive, informed lifestyle decisions.”
Google Cloud’s other partners in life sciences include Bayer, Mayo Clinic, and Rad AI, amongst others. In October, the company announced its Vertex AI Search for Healthcare platform was available for general use while also expanding features for its Healthcare Data Engine.
GenAI is the talk of the town within the healthcare industry, with increasing adoption across the pharmaceutical and medtech sectors.
A 2023 report by GlobalData predicts that global revenue for AI platforms across healthcare will reach $18.8bn by 2027, with GenAI software a significant driver of growth. Experts have previously said however that regulatory frameworks are struggling to keep up with the technology’s advancement.
Earlier this year, Roche received regulatory approval for its own AI solution in diabetes care. The Swiss company received a CE marking for the AI-enabled Accu-Chek SmartGuide CGM solution. Unlike Dexcom’s platform, however, Roche is not using GenAI. The company’s AI-powered predictive tool provides patients with a forecast of their blood glucose levels for up to two hours.
Dexcom, meanwhile, has been diversifying its technology by recently partnering with ŌURA, maker of the Oura smart ring. The San Diego-headquartered device developer has sought potential in combining its glucose measuring capabilities with ŌURA’s technology and invested $75m in the latter company’s Series D funding round last month.
